Ring Is Alcohol Moiety Patents (Class 514/548)
  • Patent number: 10555931
    Abstract: The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer. The present invention also relates to a method for the treatment of cancer comprising administering to a subject in need thereof, a therapeutically effective amount of a CDK inhibitor and a therapeutically effective amount of at least one antioxidant enzyme inhibitor. The pharmaceutical combination of the present invention exhibits synergistic effect when used in the treatment of cancer.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: February 11, 2020
    Assignee: PIRAMAL ENTERPRISES LIMITED
    Inventors: Owe Orwar, Sreesha Srinivasa, Prabha Mishra
  • Patent number: 10195170
    Abstract: Methods and compositions for inhibiting expression of ASC, expression of NLRP3, and/or formation of NLRP3 inflammasome complex by using diacerein or its analogs are provided. Also provided are methods and compositions for the treatment and/or prevention of a disorder mediated by ASC and/or NLRP3, and/or by formation of NLRP3 inflammasome complex by using diacerein or its analogs.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: February 5, 2019
    Assignee: TWI Biotechnology, Inc.
    Inventors: Chih-Kuang Chen, Jing-Yi Lee, Wei-Shu Lu, Carl Oscar Brown, III
  • Patent number: 10130605
    Abstract: Compositions for use in treating and/or alleviating a symptom of inflammatory bowel disease, colitis, and/or enterocolitis in a subject in need thereof are disclosed. The composition comprises a therapeutically effective amount of an anthraquinone derivative or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable vehicle. In one embodiment, the composition comprises diacerein. Also disclosed is a first composition comprising an anthraquinone derivative selected from the group consisting of diacerein, aloe-emodin, emodin, and rhein, and a first pharmaceutically acceptable vehicle; and a second composition comprising mesalazine, and a second pharmaceutically acceptable vehicle, in combination for use in treating and/or alleviating a symptom of inflammatory bowel disease, colitis, and/or enterocolitis.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: November 20, 2018
    Assignee: TAIRX, INC.
    Inventors: Yi-Wen Chu, Du-Shieng Chien
  • Patent number: 10092527
    Abstract: The present invention describes an approach to increase taurine or hypotaurine production in prokaryotes. More particularly, the invention relates to genetic transformation of organisms with genes that encode proteins that catalyze the conversion of cysteine to taurine, methionine to taurine, cysteamine to taurine, or alanine to taurine. The invention describes methods for the use of polynucleotides that encode cysteine dioxygenase (CDO) and sulfinoalanine decarboxylase (SAD) polypeptides in prokaryotes to increase taurine, hypotaurine or taurine precursor production. The preferred embodiment of the invention is in plants but other organisms may be used. Increased taurine production in prokaryotes could be used as nutraceutical, pharmaceutical, or therapeutic compounds or as a supplement in animal feed.
    Type: Grant
    Filed: January 12, 2016
    Date of Patent: October 9, 2018
    Assignee: PLANT SENSORY SYSTEMS, LLC
    Inventors: Frank J. Turano, Kathleen A. Turano, Peter S. Carlson, Alan M. Kinnersley
  • Patent number: 9850213
    Abstract: The present invention belongs to the technical field of organic chemistry, and specifically relates to a method for preparing rosuvastatin sodium.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: December 26, 2017
    Assignee: JIANGXI BOYA SEEHOT PHARMACEUTICAL CO., LTD.
    Inventors: Fener Chen, Fangjun Xiong, Jie Li, Pingping Zhan, Lingjun Xu, Qiuqin He, Wenxue Chen, Xiayun Huang, Yan Wu
  • Patent number: 9750761
    Abstract: One aspect of the disclosure relates to methods of treating a fibrotic condition in an individual. The methods include administering to an individual having a fibrotic condition an effective amount of a lactic dehydrogenase (LDH) inhibitor, wherein the fibrotic condition involves an internal organ or tissue, or ocular tissue, and said administering is effective to treat the fibrotic condition. Methods of administration and pharmaceutical compositions and systems for practicing such methods are also disclosed.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: September 5, 2017
    Assignee: University of Rochester
    Inventors: Robert M. Kottmann, Patricia J. Sime, Richard P. Phipps
  • Patent number: 9592233
    Abstract: Provided is a pharmaceutical combination preparation including fimasartan and rosuvastatin as active ingredients together with meglumine. The combination preparation exhibits an outstanding effect in treating cardiovascular disease by improving the disintegration and the dissolution which obtained better drug bioavailability and drug safety.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 14, 2017
    Assignee: Boryung Pharmaceutical Co., Ltd.
    Inventors: Jayhyuk Myung, Kyung Wan Nam, Cheol Woo Lee, Ju Won Kim
  • Patent number: 9546388
    Abstract: The present disclosure provides acyltransferases useful for synthesizing therapeutically important statin compound.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: January 17, 2017
    Assignee: Codexis, Inc.
    Inventors: Lynne Gilson, Steven J. Collier, Joly Sukumaran, Wan Lin Yeo, Oscar Alvizo, Ee Ling Teo, Robert J. Wilson, Junye Xu
  • Patent number: 9447019
    Abstract: The present invention relates to fluorine substituted CBD compounds, compositions thereof and uses thereof for the preparation of medicaments.
    Type: Grant
    Filed: January 8, 2014
    Date of Patent: September 20, 2016
    Assignees: UNIVERSIDADE DE SAO PAULO-USP, UNIVERSIDADE FEDERAL DO RIO GRANDE DO SUL-UFRGS, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD
    Inventors: Raphael Mechoulam, Antonio Waldo Zuardi, Flavio Pereira Kapczinski, Jaime Eduardo Cecilio Hallak, Francisco Silveira Guimaraes, Jose Alexandre de Souza Crippa, Aviva Breuer
  • Patent number: 9375496
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R5, X1, X2, X3 and X4 are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.
    Type: Grant
    Filed: September 9, 2014
    Date of Patent: June 28, 2016
    Assignees: British Columbia Cancer Agency Branch, The University of British Columbia
    Inventors: Raymond John Andersen, Carmen Adriana Banuelos, Javier Garcia Fernandez, Yusuke Imamura, Jian Kunzhong, Nasrin R. Mawji, Marianne Dorothy Sadar, Jun Wang, Amy (Hsing Chen) Tien
  • Patent number: 9181172
    Abstract: The conjugates of present invention are formed by the combination of rhein or their analogues with the organic bases or amino acids in molecular force between them. The methods for preparing the conjugates and their uses for manufacturing medicines in the treatment of diabetic nephrosis, recovery of gastrointestinal function and prevention of intestinal adhesion, as well as treatment of osteoarthritis, rheumatic arthritis and rheumatoid arthritis are also described. Rhein or their analogues as the left part of general formula (I) is selected from (1) the compounds of rhein or their analogues, in which one or two substituents of R2˜R3 and R6˜R7 are COOH at least two substituents of R1˜8 are —H; or (2) the rhein-containing extract derived from plants. In general formula (I), M represents nitrogen-containing organic bases or basic amino acids.
    Type: Grant
    Filed: July 10, 2006
    Date of Patent: November 10, 2015
    Inventor: Xiaodong Cong
  • Publication number: 20150133527
    Abstract: Methods are provided herein for treating cardiac arrhythmias, such as for treating an arrhythmia syndrome, for example Brugada syndrome, in a subject. In some embodiments, the methods include selecting a subject with Brugada syndrome and administering to the subject an effective amount of an agent that increases the expression or activity of SIRT1 in the subject. In some embodiments, the agent increases Nav1.5 activation. In some embodiments, the agent increases the expression or activity of SRIT1 and increases Nav1.5 activation.
    Type: Application
    Filed: May 6, 2013
    Publication date: May 14, 2015
    Inventors: Barry London, Kaikobad J. Irani
  • Patent number: 9029413
    Abstract: Alterations of certain metabolite concentrations and fluxes that occur in response to viral infection are described. Host cell enzymes in the involved metabolic pathways are selected as targets for intervention; i.e., to restore metabolic flux to disadvantage viral replication, or to further derange metabolic flux resulting in “suicide” of viral-infected cells (but not uninfected cells) to limit viral propagation. While any of the enzymes in the relevant metabolic pathway can be selected, pivotal enzymes at key control points in these metabolic pathways are preferred as candidate antiviral drug targets. Inhibitors of these enzymes are used to reverse, or redirect, the effects of the viral infection. Drug candidates are tested for antiviral activity using screening assays in vitro and host cells, and in animal models. Animal models are then used to test efficacy of candidate compounds in preventing and treating viral infections. Antiviral activity of enzyme inhibitors is demonstrated.
    Type: Grant
    Filed: April 3, 2012
    Date of Patent: May 12, 2015
    Assignee: The Trustees of Princeton University
    Inventors: Josh Munger, Bryson Bennett, Thomas Shenk, Joshua Rabinowitz
  • Publication number: 20150119442
    Abstract: The present invention relates to biodegradable biocide agents against marine woodborers. In particular, the present invention relates to novel slow releasing biocide impregnating solutions against marine woodborers, and methods of creating anti marine woodborer environments.
    Type: Application
    Filed: May 22, 2014
    Publication date: April 30, 2015
    Applicant: Teredo Marine Protection ApS
    Inventor: Michael Igelso Hvidt
  • Publication number: 20150119414
    Abstract: A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.
    Type: Application
    Filed: January 2, 2015
    Publication date: April 30, 2015
    Applicant: PIVOTAL THERAPEUTICS INC.
    Inventors: George JACKOWSKI, Rachelle MACSWEENEY, Nisar Ahmad SHAIKH, Jason YANTHA, Valerie B. SCHINI-KERTH
  • Publication number: 20150111965
    Abstract: The present invention relates to prodrug derivatives of pentamidine, their use in the treatment and/or prophylaxis of diseases such as tumor diseases, as well as leishmaniasis, trypanosomiasis, pneumocystis carinii pneumonia (PcP), and malaria.
    Type: Application
    Filed: December 23, 2014
    Publication date: April 23, 2015
    Inventors: Bernd CLEMENT, Joscha KOTTHAUS, Jürke KOTTHAUS, Dennis SCHADE
  • Publication number: 20150099806
    Abstract: A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I: R1a—[O]v-(-A-L-)m-A-[O]v—R1b??I wherein A, L, R1a, R1b, m, and v are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.
    Type: Application
    Filed: December 14, 2014
    Publication date: April 9, 2015
    Inventors: Michael D. WARD, Zina ZHU
  • Publication number: 20150094322
    Abstract: Pharmaceutical compositions of colchicine for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined or desired release profile. Methods of treating or preventing cardiovascular disease and/or inflammatory disease in mammalian subjects comprising the administration of the novel formulations disclosed herein are also provided.
    Type: Application
    Filed: December 8, 2014
    Publication date: April 2, 2015
    Inventor: Susanne Riel
  • Publication number: 20150093456
    Abstract: The present invention relates to a pharmaceutical composition for treating wounds or revitalizing skin comprising the Euphorbia kansui extract, the fractions thereof, or the diterpene compound isolated therefrom as an active ingredient. The Euphorbia kansui extract may act on epithelial cells to induce PKD1 activity required for improving the reproduction capability of differentiated epithelial cells, and thus may induce the phosphorylation of lower ERK1 and the generation of Cycline D, thus exhibiting an excellent ability to activate the reproduction of damaged skin. Therefore, the Euphorbia kansui extract may be used effectively as an active ingredient in a pharmaceutical composition for treating wounds or reproducing skin, a health food for recovering skin damage or reproducing skin, or a functional cosmetic for inducing skin cell activity.
    Type: Application
    Filed: December 3, 2014
    Publication date: April 2, 2015
    Inventors: Jae Wha KIM, Sei Ryang Oh, Kyung Seop AHN, Ho Bum KANG, Ok-Kyoung KWON, Seung Ho KIM, Jang Mi SON, Hyuk Hwan SONG, Hee Gu LEE, Byeong Hwa Jeon, Da Jung Ji, Khiev Piseth
  • Patent number: 8945623
    Abstract: The invention provides compositions, kits, and methods for treatment of neuronal injury. In one embodiment, the composition comprises a biomembrane sealing agent, such as PEG, and a bioactive agent, such as a magnesium compound. The biomembrane sealing agent and/or the bioactive agent an intravenous administration, an intramuscular administration, an intrathecal administration, a subcutaneous administration, an epidural administration, a parenteral administration, a direct application onto or adjacent to a site of the pathological condition, and any combinations thereof. Alternatively, the biomembrane sealing agent and/or the bioactive agent may be delivered from a pump or an implant.
    Type: Grant
    Filed: May 3, 2006
    Date of Patent: February 3, 2015
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Josee Roy, William F. McKay, Jeffrey C. Marx
  • Publication number: 20150031651
    Abstract: The invention relates to prodrugs of vitamin K2, in particular prodrugs of MK-7 in which the diketone is converted to a monosubstituted or disubstituted ester type derivative. These compounds are shown to give MK-7 in plasma.
    Type: Application
    Filed: March 4, 2013
    Publication date: January 29, 2015
    Inventors: Mona Moller, Marcel Sandberg, Inger Reidun Aukrust
  • Patent number: 8940791
    Abstract: This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements.
    Type: Grant
    Filed: July 14, 2011
    Date of Patent: January 27, 2015
    Assignee: Signature R&D Holdings, LLC
    Inventor: V. Ravi Chandran
  • Patent number: 8916609
    Abstract: A method of preventing or inhibiting L-cystine crystallization is disclosed, using the compounds of formula I: R1a—[O]v-(-A-L-)m-A-[O]v—R1b??I, wherein A, L, R1a, R1b, m, and v are as described herein. The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to L-cystine crystallization, such as comprising (but not limited to) kidney stones.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: December 23, 2014
    Assignee: New York University
    Inventors: Michael D. Ward, Zina Zhu
  • Publication number: 20140371311
    Abstract: The present invention relates to an injenane-type diterpene compound derived from Euphorbia kansui Liou, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the injenane-type diterpene compound. Furthermore, the present invention relates to a method for preventing or treating viral infectious diseases including administering the composition to a subject having a viral infectious disease occurrence or a risk thereof with a therapeutically effective dose.
    Type: Application
    Filed: September 28, 2012
    Publication date: December 18, 2014
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Sei Ryang Oh, Jae Wha Kim, Hyeong Kyu Lee, Piseth Khiev, Doo Young Kim, Jung Hee Kim, Jae Sung Song, Kyung Seop Ahn
  • Publication number: 20140370060
    Abstract: The present invention relates to a method of stabilising a tear film in an individual having an ocular surface inflammatory disorder by providing a compound to an ocular surface of the individual to reduce the synthesis of a cholesterol by a meibum-producing tissue.
    Type: Application
    Filed: February 1, 2013
    Publication date: December 18, 2014
    Inventors: Kenneth Gek-Jin Ooi, Stephanie Louise Watson
  • Publication number: 20140350032
    Abstract: The present invention relates to a compound characterized by the following Formula I: or a pharmaceutically acceptable salt thereof, wherein X, Y, and Z are as described herein. Compounds of the present invention are useful for the treatment of HIV.
    Type: Application
    Filed: December 14, 2012
    Publication date: November 27, 2014
    Inventors: Nianhe Han, Brian Alvin Johns, Jun Tang
  • Publication number: 20140335080
    Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, J1, J2, X, Z, n1 and n2 are as defined herein, and wherein at least one of R1, R2 or R3 is an alkyl, alkenyl, aryl or aralkyl ester, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.
    Type: Application
    Filed: May 9, 2014
    Publication date: November 13, 2014
    Applicants: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Raymond J. Andersen, Marianne D. Sadar, Javier Garcia Fernandez, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos
  • Publication number: 20140336148
    Abstract: The present invention relates to novel pharmaceutical combinations with synergistic action of diacerein or a pharmaceutically acceptable salt of diacerein and non-steroidal inflammatory drugs, having analgesic, anti-inflammatory, antipyretic, and osteoarthritis-treating activities.
    Type: Application
    Filed: December 25, 2012
    Publication date: November 13, 2014
    Inventors: Umit Cifter, Ali Turkyilmaz, Nur Pahlivan Akalin, Sibel Zenginer, Onur Mutlu
  • Publication number: 20140328778
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative represented by Formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the therapeutic and/or prophylactic treatment of, inter alia, dermatitis.
    Type: Application
    Filed: July 17, 2014
    Publication date: November 6, 2014
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Publication number: 20140328823
    Abstract: The present invention relates to the use of a 2,5-dihydroxybenzene derivative of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, or prodrug thereof for the treatment and/or prophylaxis of, inter alia, skin cancer.
    Type: Application
    Filed: July 15, 2014
    Publication date: November 6, 2014
    Inventors: Pedro Cuevas Sànchez, Guillermo Gimenez Gallego, Inigo Saenz de Tejada Gorman, Javier Angulo Frutos, Serafin Valverde Lopez, Antonio Romero Garrido, Rosa Maria Lozano Puerto
  • Publication number: 20140328928
    Abstract: An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.
    Type: Application
    Filed: July 22, 2014
    Publication date: November 6, 2014
    Inventors: Christopher J. Milley, Scott E. Peters
  • Publication number: 20140323390
    Abstract: The invention provides a novel class of compounds, immunogenic compositions and pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors 2. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine.
    Type: Application
    Filed: July 9, 2014
    Publication date: October 30, 2014
    Applicant: IRM LLC
    Inventors: Tom Yao-Hsiang WU, Yefen Zou, Timothy Z. Hoffman, Jianfeng Pan
  • Publication number: 20140323413
    Abstract: Disclosed herein are methods and compositions for the diagnosis and treatment of Vascular Associated Maculopathy, or a symptom thereof, in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of one or more symptoms associated with Vascular Associated Maculopathy Disclosed in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of severe maculopathy or last stage maculopathy in a subject. Disclosed herein are methods and compositions for the diagnosis and treatment of resolving aberrant choriocapillaris lobules in a subject.
    Type: Application
    Filed: March 15, 2012
    Publication date: October 30, 2014
    Applicant: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Gregory Hageman, Yingbin Fu
  • Patent number: 8858994
    Abstract: The present invention relates to novel formulations comprising ezetimibe as active ingredient. In particular the invention relates to a pharmaceutical composition comprising 5 to 20 wt-% ezetimibe, 50 to 85 wt-% diluent, 3 to 25 wt-% disintegrant, 1 to 10 wt-% binder, and 0.5 to 1 wt-% lubricant, characterized in that the ezetimibe has a particle size distribution of d(0.9) of 5 ?m to 35 ?m and d(0.5) of 3 ?m to 20 ?m, as well as methods for preparing said formulations.
    Type: Grant
    Filed: December 9, 2008
    Date of Patent: October 14, 2014
    Assignee: Ratiopharm GmbH
    Inventors: Ganesh Gat, Pasupuleti Giridhara Rao, Javed Hussain
  • Patent number: 8853270
    Abstract: The present invention relates to stilbene and quinine compounds related to combretastatin A-4 and their use as anticancer compounds and prodrugs. The compounds include those with an alkyl group on the double bond of cis- or trans-stilbenes, compounds with one or more (and preferably 2 or 3) alkyl group substituents on the stilbene A ring, compounds with an alkoxy group other than methoxy at position 3, 4, and/or 5 of the stilbene A ring, compounds (or prodrugs) in which BBOC amino acid esters are formed with the phenolic hydroxyl at the 3-position of the B ring and compounds (or prodrugs) based on a benzoquinone B ring. The present invention further relates to the photochemical reactions of stilbene compounds, either the above compounds disclosed for the first time herein or compounds based on prior stilbenes.
    Type: Grant
    Filed: August 17, 2012
    Date of Patent: October 7, 2014
    Assignee: University of Salford
    Inventors: John Anthony Hadfield, Alan Thomson McGown, Stephen Patrick Mayalarp, Edward John Land, Ian Hamblett, Keira Gaukroger, Nicholas James Lawrence, Lucy Annette Hepworth, John Butler
  • Patent number: 8846758
    Abstract: Methods for treating abnormal glycosylated hemoglobin (HbA1c) levels in a patient in need thereof, wherein the provided methods comprise administering to a patient in need a therapeutically effective amount of an Interleukin-1? modulator. Also, the invention provides compositions comprising at least one lipid modifying agent and an IL-1? modulator.
    Type: Grant
    Filed: July 19, 2012
    Date of Patent: September 30, 2014
    Assignee: TWi Biotechnology, Inc.
    Inventors: Mannching Sherry Ku, Chih-Kuang Chen, Wei-Shu Lu, Chih-Ming Chen, I-Yin Lin
  • Publication number: 20140249105
    Abstract: Compounds, ceramide analogues, having a cyclic structure derived from cyclopropane, cyclobutane or cyclopentane, the ring bearing two chains consisting of an amide function. Each amide function is attached to the ring by the nitrogen atom of the function and carries a hydrocarbon chain derived from a fatty acid. The amide functions can be cis or trans relative to one another. Processes for the preparation of these novel compounds as well as pharmaceutical and/or cosmetic compositions containing them.
    Type: Application
    Filed: July 25, 2011
    Publication date: September 4, 2014
    Applicant: Diverchim
    Inventors: Jean-Louis Brayer, Natacha Frison, Benoit Folleas
  • Patent number: 8822692
    Abstract: The present invention relates to new diterpenoid derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, urinary incontinence, asthma, or Alzheimer's disease and/or to prevent obstructive vascular lesions consequently to arteriotomy and/or angioplasty, and to prevent organ damage in hypertensive patients.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: September 2, 2014
    Assignee: Sigma-Tau Industrie Farmaceutiche Riunite, S.p.A.
    Inventors: Alberto Cerri, Mauro Gobbini, Marco Torri, Patrizia Ferrari, Mara Ferrandi, Giuseppe Bianchi
  • Publication number: 20140235714
    Abstract: The present application relates to compositions and methods for treating a proliferative disorder by administering to a subject a pharmaceutical composition of a dual kinase inhibitor. Catecholic butanes cane serve as dual kinase inhibitors for purposes of methods described herein. Subjects can be further treated by co-administering an EGFR inhibitor. The present application also relates to analyzing a sample with respect to levels of IGF-1R and EGFR and comparing levels of IGF-1R and EGFR to a control. Patients can be selected for treatment with a catecholic butane based on the assessment; optionally, patients can be further treated with an EGFR inhibitor, an IGF-1R inhibitor, or both.
    Type: Application
    Filed: April 25, 2014
    Publication date: August 21, 2014
    Applicant: TriAct Therapeutics, Inc.
    Inventors: Thomas F. WHITE, Edward F. SCHNIPPER, Dan HOTH
  • Publication number: 20140235605
    Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents and kits for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents and kits for their detection.
    Type: Application
    Filed: March 15, 2013
    Publication date: August 21, 2014
    Applicant: CELERA CORPORATION
    Inventor: CELERA CORPORATION
  • Patent number: 8809550
    Abstract: The present invention relates to novel substituted thioimidazolidinone compounds and pharmaceutical compositions comprising such compounds for treatment of androgen receptor-associated diseases or disorders, such as prostate cancer, benign prostatic hypertrophy, male hair loss, muscle loss, acne and hirsutism.
    Type: Grant
    Filed: September 8, 2010
    Date of Patent: August 19, 2014
    Inventor: Youzhi Tong
  • Publication number: 20140221484
    Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.
    Type: Application
    Filed: October 3, 2013
    Publication date: August 7, 2014
    Applicants: BRISTOL-MYERS SQUIBB COMPANY, CELERA CORPORATION
    Inventors: Michele CARGILL, Olga IAKOUBOVA, James J. DEVLIN, Zenta TSUCHIHASHI, Peter SHAW, Lynn Marie PLOUGHMAN, Kim E. ZERBA, Koustubh RANADE, Todd KIRCHGESSNER
  • Publication number: 20140221485
    Abstract: The invention provides novel lipophilic dopamine derivatives with improved stability and physiological half-life. The compounds may be used for organ and tissue preservation during storage and transport, or in the pre-treatment of organ and tissue donor or recipients. Moreover, they may be used as therapeutic agents for the prevention or treatment of ischaemia-related pathological conditions.
    Type: Application
    Filed: August 24, 2012
    Publication date: August 7, 2014
    Inventors: Bernhard Gunther, Bastian Theisingen, Sonja Theisinger
  • Publication number: 20140221316
    Abstract: This disclosure relates to novel compounds containing an H2S releasing moiety and a nitric oxide (NO) releasing moiety covalently linked with a core (e.g., a salicylic acid moiety) and the use of such compounds in treating inflammatory diseases, including cancers. Therapeutic potency of these compounds is significantly higher than NSAIDs containing a H2S-releasing moiety alone (HS-NSAIDs) and NSAID containing a NO-releasing moiety alone (NO-NSAIDs). The compounds, in addition, exhibit reduced side effect, e.g., reduced stomach ulcers, upon administration.
    Type: Application
    Filed: August 15, 2012
    Publication date: August 7, 2014
    Applicant: RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK
    Inventors: Khosrow Kashfi, Ravinder Kodela
  • Patent number: 8785443
    Abstract: Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions comprising prodrugs of methyl hydrogen fumarate, and methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof for treating diseases such as psoriasis, asthma, multiple sclerosis, inflammatory bowel disease, and arthritis are disclosed.
    Type: Grant
    Filed: October 14, 2011
    Date of Patent: July 22, 2014
    Assignee: XenoPort, Inc.
    Inventors: Archana Gangakhedkar, Xuedong Dai, Noa Zerangue, Peter A. Virsik
  • Publication number: 20140200254
    Abstract: The present invention relates to pharmaceutical compositions comprising D-serine transporter inhibitors and therapeutic methods using such pharmaceutical compositions in methods for the treatment of central nervous system disorders.
    Type: Application
    Filed: March 17, 2014
    Publication date: July 17, 2014
    Applicant: Allergan, Inc.
    Inventors: ALAN C. FOSTER, YONG-XIN Li, URSULA STAUBLI, VEENA VISWANATH, LAUREN LUHRS
  • Publication number: 20140199378
    Abstract: This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor, cell circulating, cell moving and inflammatory diseases.
    Type: Application
    Filed: July 13, 2012
    Publication date: July 17, 2014
    Applicant: PACIFIC ARROW LIMITED
    Inventors: Pui-Kwong Chan, May Sung Mak
  • Patent number: 8772340
    Abstract: A process for the preparation of (R)-2-(3-diisopropylamino-1-phenylpropyl)-4-(hydroxymethyl)-phenol isobutyrate (Fesoterodine) or a pharmaceutically acceptable salt thereof having low content in impurities.
    Type: Grant
    Filed: November 14, 2011
    Date of Patent: July 8, 2014
    Assignee: Dipharma Francis S.r.l.
    Inventors: Marco Artico, Emanuele Attolino, Pietro Allegrini, Gabriele Razzetti
  • Patent number: 8765810
    Abstract: The present invention is directed to compounds that are allosteric inhibitors of tumor necrosis factor receptor I, compositions comprising such compounds, and methods of using such compounds and compositions thereof in the treatment of TNF-? mediated conditions.
    Type: Grant
    Filed: October 18, 2012
    Date of Patent: July 1, 2014
    Assignees: The Trustees Of The University Of Pennsylvania, Cephalon, Inc.
    Inventors: Mark I. Greene, Ramachandran Murali, Xin Cheng, Raphael Ottenbrite, Yingxin Xiaio
  • Publication number: 20140179723
    Abstract: Statin compositions are disclosed for stimulating neurite growth from spiral ganglion neurons in the inner ear and methods for preventing damage to or treating damage of auditory neurons and/or hair cells of the cochlea following acoustic or toxic insult.
    Type: Application
    Filed: December 13, 2013
    Publication date: June 26, 2014
    Inventors: Donna S. Whitlon, Claus-Peter Richter